Tirabrutinib + Placebo
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Central Nervous System Lymphoma
Conditions
Primary Central Nervous System Lymphoma
Trial Timeline
Oct 6, 2023 → Feb 1, 2030
NCT ID
NCT06940791About Tirabrutinib + Placebo
Tirabrutinib + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Primary Central Nervous System Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06940791. Target conditions include Primary Central Nervous System Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Primary Central Nervous System Lymphoma were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06940791 | Phase 2 | Recruiting |
| NCT02626026 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Central Nervous System Lymphoma